[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350972-105":59,"doc-detail-350972-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mylk4-promotes-colorectal-cancer-progression-by-regulating-lipid-metabolism-reprogramming-via-targeting-ferroptosis","MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis","","Advancement in targeted drugs for colorectal cancer (CRC) is constrained by incomplete understanding of CRC pathophysiology and by limited effectiveness of tyrosine kinase inhibitors (TKIs) due to resistance. MYLK4-mediated lipid metabolic reprogramming enables CRC resistance to TKI-induced ferroptosis. MYLK4 interacts with TRIM15 in an MDM2-dependent manner, promoting p53 ubiquitination and degradation, while p53 restrains SCD1 transcription through promoter binding. Elevated MYLK4 and SCD1 predict regorafenib resistance and poor prognosis, and combined regorafenib plus SCD1 inhibition shows anti-tumor efficacy in organoids and xenografts of wild-type p53 patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mylk4-promotes-colorectal-cancer-progression-by-regulating-lipid-metabolism-reprogramming-via-targeting-ferroptosis/350972/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mylk4-promotes-colorectal-cancer-progression-by-regulating-lipid-metabolism-reprogramming-via-targeting-ferroptosis/350972.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does MYLK4 influence TKI-induced ferroptosis in colorectal cancer?","Question",{"text":113,"@type":114},"MYLK4-mediated lipid metabolic reprogramming confers resistance to TKI-induced ferroptosis in CRC. The study links this effect to downstream changes involving p53 and SCD1.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What molecular mechanism connects MYLK4 with p53 regulation?",{"text":118,"@type":114},"MYLK4 directly interacts with TRIM15 in an MDM2-dependent manner, enhancing p53 ubiquitination and degradation. This reduces p53’s transcriptional suppression of SCD1.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are SCD1 levels important for regorafenib response and prognosis?",{"text":122,"@type":114},"SCD1 expression increases alongside MYLK4. Their concurrent expression predicts regorafenib resistance and poor prognosis in colorectal cancer.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350972,1790195484,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Neoplasia 73 (2026) 101270  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis |  |  | |\n| --- | --- | --- | --- |\n| *\u003Cbr>Bishi Wang , Kongxiu Wu , Xin Liu , Yuhai Shen , Yanliang Li \u003Cbr>Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: MYLK4\u003Cbr>Colorectal cancer Regorafenib Ferroptosis TRIM15 |  | The advancement of novel pharmaceuticals and targeted therapeutic approaches is considerably obstructed by the insufficient comprehension of the intricate pathophysiology of colorectal cancer (CRC). The therapeutic effectiveness of tyrosine kinase inhibitors (TKI)-based systemic treatment for advanced CRC is limited by medication resistance. Research has revealed that therapeutic strategies aimed at the myosin light chain kinase family member 4 (MYLK4) and its corresponding response element can suppress tumour proliferation and yield significant clinical advantages for cancer patients. This study reveals that MYLK4-mediated lipid metabolic reprogramming confers resistance to TKI-induced ferroptosis in CRC. MYLK4 directly interacts with tripartite motif containing 15 (TRIM15) in a way reliant on mouse double minute 2 homolog (MDM2), hence enhancing p53 ubiquitination and degradation. Significantly, p53 suppresses the transcription of stearoyl-CoA desaturase 1 (SCD1) through binding to its promoter. Elevated SCD1 levels correlate with increased MYLK4 levels, and their concurrent expression forecasts regorafenib resistance and poor prognosis in colorectal cancer. Regorafenib and SCD1 inhibitor (SCD1 inhibitor-3) co-treatment demonstrate promising anti-tumor efficacy in organoids and xenografted tumours derived from wild-type p53 colorectal cancer patients. Patients with colorectal cancer exhibiting elevated MYLK4 activity and wild-type p53 may derive clinical benefits from this combination therapy. These results suggest that MYLK4 may serve as a promising therapeutic target for the treatment of colorectal cancer. |  |\n\nIntroduction  \nColorectal cancer (CRC), the most common malignancy among the population, is acknowledged as a significant global public health issue. Colorectal cancer can metastasise from the intestinal mucosa surface to the stomach, liver, prostate gland, and uterus if not timely diagnosed [1, 2]. Although the molecular mechanisms of colorectal cancer growth have been extensively studied, additional study is necessary to discover novel and effective therapeutic strategies. Recent epidemiological investigations have associated oxidative stress with abnormalities of colon metabolism [3,4]. Colorectal cancer is more prevalent globally, primarily due to dietary issues and the consequent emergence of metabolic syndrome linked to irregular routines [5,6]. Recent reports have elucidated the genetic alterations linked to colorectal cancer, encompassing mutations in p53, KRAS, and EGFR [7,8]. Colorectal cancer is a heterogeneous tumour characterised by a poor therapeutic response and a  \nhigh mortality rate. The disruption of immunological, metabolic, and genetic homeostasis is considered a significant element in the aetiology of colorectal cancer, despite the unknown origins of the disease and its resultant tumours. Currently, tyrosine kinase inhibitors (TKIs) are widely utilised in the systemic treatment of colorectal cancer patients, as reported by the Chinese Society of Clinical Oncology (CSCO) (2024), including regorafenib, fruquintinib, entrectinib, tucatinib, osimertinib, repotrectinib, larotrectinib, and sunitinib [1,9]. Unfortunately, these drugs provided ","cbCaisFBA8LvKJTX","https://ap.wps.com/l/cbCaisFBA8LvKJTX","pdf",10332379,17,"English","# Introduction\n# Materials and methods\n# Results\n## MYLK4 regulates lipid metabolism reprogramming and ferroptosis\n## MYLK4–TRIM15–MDM2 axis promotes p53 ubiquitination and degradation\n## SCD1 links MYLK4 to regorafenib resistance\n## Combination therapy with regorafenib and SCD1 inhibitor\n# Discussion\n# Conclusion","[{\"question\":\"How does MYLK4 influence TKI-induced ferroptosis in colorectal cancer?\",\"answer\":\"MYLK4-mediated lipid metabolic reprogramming confers resistance to TKI-induced ferroptosis in CRC. The study links this effect to downstream changes involving p53 and SCD1.\"},{\"question\":\"What molecular mechanism connects MYLK4 with p53 regulation?\",\"answer\":\"MYLK4 directly interacts with TRIM15 in an MDM2-dependent manner, enhancing p53 ubiquitination and degradation. This reduces p53’s transcriptional suppression of SCD1.\"},{\"question\":\"Why are SCD1 levels important for regorafenib response and prognosis?\",\"answer\":\"SCD1 expression increases alongside MYLK4. Their concurrent expression predicts regorafenib resistance and poor prognosis in colorectal cancer.\"}]","MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis | PDF",1790092146,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5ae6eb96a8290eb29bc2813e5740f05.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6dc552a8d67e92ce9f7e20e9625d831.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec8ae798a400e32b9221f6446bda31b9.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c61d2a7611fe1de87a9781c42f397f6f.webp",980,1306]